The effects of sex steroids on plasma levels of marker proteins of endothelial cell functioning

Thrombosis and Haemostasis

Volumn 79, Issue 5, 1998, Pages 1029-1033

  Van Kesteren, P J M ^a   Kooistra, T ^b   Lansink, M ^b   Van Kamp, G J ^a   Asscheman, H ^a   Gooren, L J G ^a   Emeis, J J ^b   Vischer, U M ^c   Stehouwer, C D A ^a,d  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b TNO   (Netherlands)

^c UNIVERSITY OF GENEVA   (Switzerland)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYPROTERONE ACETATE; ENDOTHELIN 1; ETHINYLESTRADIOL; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN; SEX HORMONE; TESTOSTERONE; TESTOSTERONE ESTER; UROKINASE; VON WILLEBRAND FACTOR;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; ENDOTHELIUM CELL; FEMALE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN PROCESSING; PROTEIN SECRETION; TRANSSEXUALISM; VASCULAR ENDOTHELIUM;

EID: 0031976342     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1615115     Document Type: Article

References (37)

1. Gangar KF, Reid BA, Crook D, Hillard TC, Whitehead MI. Oestrogens and atherosclerotic vascular disease - local vascular factors. Ballières Clin Endocrinol Metab 1993; 7: 47-59.
2. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993; 341: 1165-8.
3. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 332: 635-41.
4. Jansson JH, Nilsson TK, Johnson O. von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J 1991; 66: 351-5.
5. Jansson JH, Olofsson BO, Nilsson TK. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease. A 7-year follow-up. Circulation 1993; 88: 2030-4.
6. Omland T, Lie RT, Aakvaag A, Aarsland T, Dickstein K. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation 1994; 89: 1573-9.
7. Kooistra T, Lansink M, van Kesteren P, Koolwijk P, Toet K, Peters E, Hegeman R, Emeis JJ, Stehouwer C, Gooren L, van Hinsbergh VWM. Effects of steroid hormones on the secretion of haemostatic factors in, and angiogenic properties of, human vascular endothelial cells. Gynecol Endocrinol 1996; 10 (suppl 2): 105-10.
8. Kluft C, Verheijen JH. Leiden fibrinolysis working party: blood collection and handling procedures for assessment of tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor (PAI-1). Fibrinolysis 1990; 4 (suppl 2): 155-61.
9. Ingerslev J. A sensitive elisa for von Willebrand factor (vWF:Ag). Scand J Clin Lab Invest 1987; 47: 143-9.
10. Borchiellini A, Fijnvandraat K, ten Cate JW, Pajkrt D, van Deventer SJH, Pasterkamp G, Meyer-Huizinga F, Zwart-Huinink L, Voorberg J, van Mourik JA. Quantitative analysis of von Willebrand factor propeptide release in vivo: effect of experimental endotoxemia and administration of 1-deamino-8-D-arginine vasopressin in humans. Blood 1996; 88: 2951-8.
11. Vischer UM, Ingerslev J, Wollheim CB, Mestries J-C, Tsakiris DA, Haefeli WE, Kruithof EKO. Acute von Willebrand factor secretion from the endothelium in vivo: assessment through plasma propeptide (vWF:AgII) levels. Thromb Haemost 1997; 77: 387-93.
12. Bos R, Hoegee-de Nobel E, Laterveer R, Meijer P, Nieuwenhuizen W. A one-step enzyme immunoassay for the determination of total tissue-type plasminogen activator (t-PA) antigen in plasma. Blood Coag Fibrinol 1992; 2: 303-7.
13. Nieuwenhuizen W, Laterveer R, Hoegee-de Nobel E, Bos R. A one-step enzyme immunoassay for total plasminogen activator inhibitor-1 antigen in human plasma. Blood Coag Fibrinol 1995; 6: 268-72.
14. Koolwijk P, van Erck MGM, de Vree WJA, Vermeer MA, Weigh HA, Hanemaaijer R, van Hinsberg VWM. Cooperative effect of tumor necrosis factor-α and angiogenic growth factors on the formation of tubular structures of human microvascular endothelial cells in a three-dimensional fibrin matrix. Role of pericellular urokinase activity. J Cell Biol 1996; 132: 1177-88.
15. Emeis JJ, van den Eijnden-Schrauwen Y, Kooistra T. Tissue-type plasminogen activator and the vessel wall: synthesis, storage and secretion. In: Vascular control of haemostasis. Van Hinsbergh VWM (ed). Victoria, Australia, Gordon and Breach Science Publishers 1996; 187-206.
16. 2,-macroglobulin receptor mediates cellular uptake of pro-urokinase. J Biol Chem 1993; 268: 21862-7.
17. Orth K, Willnow T, Herz J, Gething MJ, Sambrook JF. Low density lipoprotein receptor-related protein is necessary for the internalization of both tissue-type plasminogen activator-inhibitor complexes and free tissue-type plasminogen activator. J Biol Chem 1994; 269: 21117-22.
18. Kluft C. Constitutive synthesis of tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor type 1 (PAI-1): conditions and therapeutic targets. Fibrinolysis 1994; 8 (suppl 2): 1-7.
19. Aro J, Haapiainen R, Rasi V, Rannikko S, Alfthan O. The effect of parenteral estrogen versus orchiectomy on blood coagulation and fibrinolysis in prostatic cancer patients. Eur Urol 1990; 17: 161-5.
20. Blomback M, Hedlund PO, Sawe U. Changes in blood coagulation and fibrinolysis in patients on different treatment regimens for prostatic cancer. Predictors for cardiovascular complications? Thromb Res 1988; 49: 111-21.
21. Gevers Leuven JA, Kluft C, Bertina RM, Hessel LW. Effects of two low-dose oral contraceptives on circulating components of the coagulation and fibrinolytic systems. J Lab Clin Med 1987; 109: 631-6.
22. Gebara OC, Mittleman MA, Sutherland P, Lipinska I, Matheney T, Xu P, Welty FK, Wilson PW, Levy D, Muller JE. Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. Circulation 1995; 91: 1952-8.
23. Kluft C, Lansink M. Effect of oral contraceptives on haemostasis variables. Thromb Haemost 1997; 78: 315-26.
24. Anderson RA, Ludlam CA, Wu FCW. Haemostatic effects of supraphysiological levels of testosterone in normal men. Thromb Haemost 1995; 74: 693-7.
25. Sporn LA, Marder VJ, Wagner DD. Differing polarity of the constitutive and regulated secretory pathways for von Willebrand factor in endothelial cells. J Cell Biol 1989; 108: 1283-9.
26. Stel HV, Sakariassen KS, de Groot PG, van Mourik JA, Sixma JJ. von Willebrand factor in the vessel wall mediates platelet adherence. Blood 1985; 65: 85-90.
27. Wagner DD, Fay PJ, Sporn LA, Sinha S, Lawrence SO, Marder VJ. Divergent fates of von Willebrand factor and its propolypeptide (von Willebrand antigen II) after secretion from endothelial cells. Proc Natl Acad Sci USA 1987; 84: 1955-9.
28. Silveira AM, Elgue G, Hamsten A, Blombäck M. von Willebrand factor in plasma and urine of men with premature coronary artery disease. Thromb Haemost 1992; 67: 161-5.
29. Harrison RL, McKee PA. Estrogen stimulates von Willebrand factor production by cultured endothelial cells. Blood 1984; 63: 657-65.
30. Kooistra T, Bosma PJ, Jespersen J, Kluft C. Studies on the mechanism of action of oral contraceptives with regard to fibrinolytic variables. Am J Obstet Gynecol 1990; 163: 404-13.
31. Chandler WL, Alessi MC, Aillaud MF, Henderson P, Vague P, Juhan-Vague I. Clearance of tissue plasminogen activator (TPA) and TPA/plasminogen activator inhibitor type 1 (PAI-1) complex. Relationship to elevated TPA antigen in patients with high PAI-1 activity levels. Circulation 1997; 96: 761-8.
32. Polderman KH, Stehouwer CDA, van Kamp GJ, Dekker GA, Verheugt FWA, Gooren LJG. Influence of sex hormones on plasma endothelin levels. Ann Intern Med 1993; 118: 429-32.
33. White MW, Zamudio S, Stevens T, Tyler R, Lindenfeld J, Leslie K, Moore LG. Estrogen, progesterone, and vascular reactivity: potential cellular mechanisms. Endocr Rev 1995; 16: 739-51.
34. Webb D. Physiological role of the endothelin system in human cardiovascular and renal haemodynamics. Curr Opin Nephrol Hypertens 1997; 6: 69-73.
35. Weiner CP, Lizasoain I, Baylis SA, Knowles RG, Charles IG, Moncada S. Induction of calcium-dependent nitric oxide synthases by sex hormones. Proc Natl Acad Sci USA 1994; 91: 5212-6.
36. Mikkola T, Turunen P, Avela K, Orpana A, Viinikka L, Ylikorkala O. 17β-estradiol stimulates prostacyclin, but not endothelin-1, production in human vascular endothelial cells. J Clin Endocrinol Metab 1995; 80: 1832-6.
37. Ferri C, Bellini C, Desideri G, Di Francesco L, Baldoncini R, Santucci A, De Mattia G. Plasma endothelin-1 levels in obese hypertensive and normotensive men. Diabetes 1995; 44: 431-6.